Sort   by:  
 Page size 
UnknownDownstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
Not available
S-EPMC11059071 | biostudies-literature
UnknownUpdate on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.
Not available
S-EPMC3286387 | biostudies-literature
UnknownTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355 | biostudies-literature
UnknownBaricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Not available
S-EPMC9333998 | biostudies-literature
UnknownComparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.
Not available
S-EPMC11209765 | biostudies-literature
UnknownEtiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease.
Not available
S-EPMC10580156 | biostudies-literature
UnknownEffect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Not available
S-EPMC7556338 | biostudies-literature
UnknownDexamethasone in Hospitalized Patients with Covid-19.
Not available
S-EPMC7383595 | biostudies-literature
UnknownAzithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC7884931 | biostudies-literature
UnknownEmpagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483 | biostudies-literature
Sort   by:  
 Page size